Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
Source: onclive.com
Asco Plenary News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Asco Plenary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Asco Plenary Today - Breaking & Trending Today